Lsl Pharma Group Inc(LSL-X)
TSX Venture

Today's Change
Delayed Last Update
Day Low0.305
Day High0.322
Open:0.310
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
Newswire.ca
LSL PHARMA GROUP ANNOUNCES VOTING RESULTS OF ITS ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS
Newswire.ca
LSL PHARMA GROUP SECURES NEW STERI-MED COMMERCIAL AGREEMENTS EXPECTED TO GENERATE OVER $4 MILLION IN RECURRING ANNUAL REVENUES AND APPOINTS ALAIN R. DUGAL AS NEW EVP & COO
Newswire.ca
LSL PHARMA GROUP REPORTS RECORD REVENUES AND FIRST QUARTER 2026 RESULTS
Newswire.ca
LSL PHARMA GROUP REPORTS ITS FOURTH QUARTER AND YEAR-END 2025 RESULTS
Newsfile
Upcoming Meeting Dates - April 20, 2026
Newswire.ca
LSL PHARMA GROUP INC. ANNOUNCES ITS PARTICIPATION IN THE "2026 BLOOM BURTON & CO. HEALTHCARE INVESTOR CONFERENCE"
Newswire.ca
JUNO OTC, A WHOLLY-OWNED SUBSIDIARY OF LSL PHARMA GROUP, SIGNS BINDING TERM SHEET WITH INSTAPILL PRIVATE LIMITED TO SUPPLY PRIVATE LABEL LORATADINE 10 MG RDT IN CANADA
Newswire.ca
LSL PHARMA GROUP GRANTS STOCK OPTIONS
Newswire.ca
LSL PHARMA GROUP SUCCESSFULLY OBTAINED U.S. FDA CERTIFICATION FOR THE MANUFACTURING OF OPHTHALMIC OINTMENTS FOR COMMERCIALIZATION IN THE UNITED STATES
Newswire.ca
LSL PHARMA GROUP ANNOUNCES CLOSING OF THE ACQUISITION OF JUNO OTC AND FINAL $2M CLOSING OF UPSIZED $12M OFFERING
Newswire.ca
LSL PHARMA GROUP CLOSES $10M OF UPSIZED $12M BROKERED OFFERING AND ENTERS INTO DEFINITIVE AGREEMENT FOR THE ACQUISITION OF JUNO OTC
Newswire.ca
LSL PHARMA GROUP ANNOUNCES ACQUISITION OF JUNO OTC INC. AND A BROKERED PRIVATE PLACEMENT OF CONVERTIBLE DEBENTURES OF $11M
Newswire.ca
LSL PHARMA GROUP REPORTS FOURTH CONSECUTIVE RECORD QUARTERLY REVENUES AND Q3 2025 FINANCIAL RESULTS
Newswire.ca
LSL PHARMA GROUP COMPLETES THE ACQUISITION OF LABORATOIRE DU-VAR INC.
Newswire.ca
HEALTH CANADA GRANTS LSL PHARMA GROUP APPROVAL TO COMMERCIALIZE SIX NEW STERILE OPHTHALMIC SOLUTIONS
Newswire.ca
LSL PHARMA GROUP ANNOUNCES APPOINTMENTS TO ITS BOARD OF DIRECTORS
Newswire.ca
LSL PHARMA GROUP CLOSES A $2.275M NON-BROKERED PRIVATE PLACEMENT
Newswire.ca
LSL PHARMA GROUP REPORTS THIRD CONSECUTIVE RECORD QUARTERLY REVENUES AND Q2 2025 FINANCIAL RESULTS
Newswire.ca
LSL PHARMA GROUP ANNOUNCES THE COMPLETION OF EARLY REDEMPTION OF ALL 11% UNSECURED CONVERTIBLE DEBENTURES

Profile

LSL Pharma Group Inc develops, manufactures and commercializes sterile pharmaceutical products, cosmetic products and natural health products. It operates in three segments CMO activities include four operating entities LSL Laboratory, Dermolab, Du-Var, and VSI; Integrated Eye-care pharmaceutical company which includes sterile Eye-care manufacturing operation; and Private Label Business includes Juno OTC which commercializes pharmaceutical products with a focus on private label, over the counter (OTC) products. It derives majority of revenue from CMO activities segment.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.